Beam Therapeutics (NasdaqGS:BEAM) launched BEAM-304, a new base-editing genetic medicine program for phenylketonuria, expanding its liver-targeted portfolio. The company entered a $500 million ...
Beam Technologies is well-positioned to benefit from growing EV adoption with innovative EV charging solutions like EV ARC and BeamSpot. Beam's financial health is strong, with no debt, expanding ...
Analysts have set 12-month price targets for Beam Therapeutics, revealing an average target of $44.5, a high estimate of $74.00, and a low estimate of $28.00. This current average reflects an increase ...
Beam Therapeutics’ BEAM proprietary base-editing technology potentially enables the development of a differentiated class of precision genetic medicines that target a single base in the genome without ...
2d
Beam Global and HEVO Inc. Launch Market-Ready Autonomous Charging Platform for Autonomous Vehicles
Beam Global, (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the ...
We recently published a list of 10 Best Growth Stocks to Invest in for the Next 10 Years. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against ...
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Beam Global (BEEM), (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and ...
Ion Beam Applications SA (IBA) showcased robust growth in its third quarter of 2024, with a significant increase in equipment order intake reaching EUR 215 million and a strong order book valued at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results